Our findings also show that IL-6 and miR-155-3p may be novel biomarkers for diagnosing glioma and that treatment targeting autophagy and the STAT3 pathway may impair the immunosuppressive tumor microenvironment and participate in antitumor immunotherapy. Here, IL6 is linked to central nervous system cancer.